Financial Daily from THE HINDU group of publications
Tuesday, Nov 01, 2005


News
Features
Stocks
Shipping
Archives
Google

Group Sites

Corporate - Outlook


Panacea Bio sees positive impact from Novartis buy of Chiron

Our Bureau

New Delhi , Oct 31

THE New Delhi-based Panacea Biotec today maintained that the announcement by Novartis AG to take over US biotechnology firm, Chiron Corp, would be beneficial to its joint venture with the latter in India.

Panacea had entered into a 50:50 joint venture with Chiron last year to provide new-generation combination vaccines in India.

The Swiss pharmaceuticals company today said that it had reached an agreement to complete a takeover of Chiron by acquiring the remaining 58 per cent in the company for $5.1 billion.

The Chiron board of directors approved the merger and recommended that the shareholders take up the offer.

Mr Rajesh Jain, Joint Managing Director, Panacea Biotec, said: "We would be positively impacted by Novartis picking up the balance equity. This takeover is not likely to have any impact on our existing joint venture agreement as Novartis is not a third party to the agreement as it already had a substantial stake in Chiron."

The joint venture company had planned to launch about six vaccines in the next few years.

Chiron is known globally for its influenza vaccines, but its portfolio comprises vaccines against meningitis, rabies, tick-borne encephalitis, polio, mumps, measles and rubella (MMR), as well as diphtheria, tetanus, and whooping cough.

On Monday, the Panacea Biotec scrip fell by 4.22 per cent at the BSE to close at Rs 272.50.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Tata Safari Dicor

Stories in this Section
Sterling Farm bags award


All Iraqi crude bought at prevailing intl prices: Reliance Ind
Ponni Sugars Erode to raise sugarcane crushing capacity
BASF India to hike capacity
Venkat Pharma bags order
Assam Co strikes oil in Amguri
Name change for Traders Hotel
HC stays AAIFR order on Jessop rights issue
HLL: Q3 numbers signal newfound aggression
Cross-holding between NTPC and BHEL — A solution to many problems
Godrej acquires FMCG co in UK
Swap ratio for Williamson, McLeod Russel merger soon
United Phosphorus acquires Argentina's Reposo for $11 m
Bajaj Hindusthan begins cane crushing in 3 new UP plants
In revamp mode — Visaka Ind plans Rs 64-cr expansion
ONGC to launch pilot project for helium production
Vishnu Fabrics plans backward integration
Ranbaxy aid to quake-hit J&K
Biodiesel foray: Emami team set to visit US, Europe for machinery
Pokarna diversifies into apparel making
ONGC confident of striking gas in Bengal Basin
Panacea Bio sees positive impact from Novartis buy of Chiron
Hero Honda retail sales cross 4 lakh units in October


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line